Protalix treats first Gaucher patient in Phase I study with PRX-112

Protalix BioTherapeutics announced that the first patient has been treated in the company's phase I clinical trial of PRX-112, or Oral GCD, the company's orally-administered enzyme product candidate for the treatment of Gaucher disease. Oral GCD is a plant cell expressed form of the glucocerebrosidase enzyme, or GCD, that is naturally encapsulated within carrot cells and administered orally. Protalix expects the phase I trial to be completed during the Q3.

View Comments (0)